Ingrid Mai

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. ncbi Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients
    Ingrid Mai
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Berlin, Germany
    Nephrol Dial Transplant 18:819-22. 2003
  2. ncbi MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients
    Ingrid Mai
    Institute of Clinical Pharmacology, Charite University Medicine Berlin, Germany
    Br J Clin Pharmacol 58:548-53. 2004
  3. ncbi Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction
    Ingrid Mai
    Institute of Clinical Pharmacology, Departmetn of Naturopathy, Charite University Medicine Berlin, Germany
    Clin Pharmacol Ther 76:330-40. 2004
  4. ncbi Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients
    Steffen Bauer
    Institute of Clinical Pharmacology, University Medical Centre Charité, Humboldt University of Berlin, Berlin, Germany
    Br J Clin Pharmacol 55:203-11. 2003
  5. ncbi The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation
    Anne Kathrin Pieper
    Department of Pediatric Nephrology, Charite, Humboldt University, Berlin, Germany
    Nephrol Dial Transplant 19:2630-3. 2004
  6. ncbi Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers
    Andreas Johne
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Campus Charite Mitte, Schumannstr 20 21, 10098, Berlin, Germany
    Eur J Clin Pharmacol 60:617-22. 2004
  7. ncbi Limitations of C2 monitoring in renal transplant recipients
    Gunilla Einecke
    Department of Nephrology, Charite, Berlin, Germany
    Nephrol Dial Transplant 20:1463-70. 2005
  8. ncbi Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene
    Andreas Johne
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Germany
    Clin Pharmacol Ther 72:584-94. 2002
  9. ncbi The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression
    Gunilla Einecke
    Department of Nephrology, Charite, Humboldt University, Schumannstrasse 20 21, D 10117 Berlin, Germany
    Nephrol Dial Transplant 19:215-22. 2004
  10. ncbi MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients
    Ingrid Mai
    , , Schumannstr. 20/21, 10098 Berlin, Germany
    J Clin Pharmacol 43:1101-7. 2003

Detail Information

Publications11

  1. ncbi Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients
    Ingrid Mai
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Berlin, Germany
    Nephrol Dial Transplant 18:819-22. 2003
    ..This study investigated the effect of St John's wort (SJW) extract on the pharmacokinetics of the immunosuppressants tacrolimus (TAC) and mycophenolic acid (MPA)...
  2. ncbi MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients
    Ingrid Mai
    Institute of Clinical Pharmacology, Charite University Medicine Berlin, Germany
    Br J Clin Pharmacol 58:548-53. 2004
    ....
  3. ncbi Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction
    Ingrid Mai
    Institute of Clinical Pharmacology, Departmetn of Naturopathy, Charite University Medicine Berlin, Germany
    Clin Pharmacol Ther 76:330-40. 2004
    ..This study compared the effects of 2 SJW preparations with high and low HYF content on the pharmacokinetics of cyclosporine (INN, ciclosporin) (CSA)...
  4. ncbi Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients
    Steffen Bauer
    Institute of Clinical Pharmacology, University Medical Centre Charité, Humboldt University of Berlin, Berlin, Germany
    Br J Clin Pharmacol 55:203-11. 2003
    ..This study investigated the effects of St John's wort extract (SJW) on the pharmacokinetics and metabolism of the immunosuppressant cyclosporin A (CSA)...
  5. ncbi The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation
    Anne Kathrin Pieper
    Department of Pediatric Nephrology, Charite, Humboldt University, Berlin, Germany
    Nephrol Dial Transplant 19:2630-3. 2004
    ..It is still unknown if sevelamer, a new calcium-free phosphate binder, interferes with the uptake of immunosuppressants. We studied its effects on the pharmacokinetics of cyclosporin A (CsA) and mycophenolate mofetil...
  6. ncbi Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers
    Andreas Johne
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Campus Charite Mitte, Schumannstr 20 21, 10098, Berlin, Germany
    Eur J Clin Pharmacol 60:617-22. 2004
    ..Hypericin and pseudohypericin pharmacokinetics were only marginally influenced by comedication with the enzyme inhibitors and inducers cimetidine and carbamazepine...
  7. ncbi Limitations of C2 monitoring in renal transplant recipients
    Gunilla Einecke
    Department of Nephrology, Charite, Berlin, Germany
    Nephrol Dial Transplant 20:1463-70. 2005
    ..The present study sought to validate the cornerstones of the current concept of C(2) monitoring...
  8. ncbi Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene
    Andreas Johne
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Germany
    Clin Pharmacol Ther 72:584-94. 2002
    ..According to earlier data, homozygous TT of the exon 26 complementary deoxyribonucleic acid (cDNA) 3435C>T polymorphism was associated with low P-gp expression in the human intestine...
  9. ncbi The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression
    Gunilla Einecke
    Department of Nephrology, Charite, Humboldt University, Schumannstrasse 20 21, D 10117 Berlin, Germany
    Nephrol Dial Transplant 19:215-22. 2004
    ..To date, limited prospective data are available with respect to risks and benefits of C2 monitoring in renal transplant recipients, and little experience exists with C2 monitoring in maintenance patients...
  10. ncbi MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients
    Ingrid Mai
    , , Schumannstr. 20/21, 10098 Berlin, Germany
    J Clin Pharmacol 43:1101-7. 2003
    ..5-37.1) in the noncarrier group. It was concluded that MDR1 haplotypes derived from the SNPs 2677G>T (exon 21) and 3435C>T (exon 26) are not associated with cyclosporine pharmacokinetics in renal transplant patients...
  11. ncbi Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children
    Guido Filler
    Department of Pediatrics, Division of Nephrology, Children s Hospital of Eastern Ontario, University of Ottawa, 401 Smyth Road, K1H 8L1, Ottawa, Ontario, Canada
    Pediatr Nephrol 18:445-9. 2003
    ..There were few side effects: one episode each of diarrhea and leukocytopenia and two viral infections. We conclude that MMF at 900 mg/m(2) per day appears to be effective in these patients...